Oculis Holding AG
NASDAQ:OCSBiotechnology
Healthcare
$7.44 -2.43%
-$0.28 today
- Market cap
- $459.29M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
52W Low $10.52High $34.48
Volume 0.15M
Average 0.65M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$62.22M
FY 2025 · Annual
Investing Cash Flow
-$59.38M
FY 2025 · Annual
Financing Cash Flow
$178.60M
FY 2025 · Annual
+230.6% YoYCash Flow Statement
CHF
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.51M) |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 328K | 804K | 3.61M | 9.78M | 16.04M |
| Change in Working Capital | (791K) | 6M | (12.99M) | 14.16M | (70.67K) |
| Accounts Receivables | 233K | (152K) | 36K | 247K | 1.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 30K | 3.04M | 3.73M | (1.71M) | (1.86M) |
| Other Working Capital | (1.05M) | 3.11M | (16.76M) | 15.62M | (106.97K) |
| Other Non-Cash Items | 4.93M | 6.47M | 43.95M | 14.09M | 15.77M |
| Operating Cash Flow | (13.83M) | (25.07M) | (53.85M) | (47.5M) | (62.22M) |
| Capital Expenditures | (28K) | (3.55M) | (48K) | (230K) | (287.47K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (54.16M) | (17.33M) | (58.05M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (3.48M) | 0 | 0 | 0 |
| Investing Cash Flow | (28K) | (3.55M) | (54.21M) | (17.56M) | (59.38M) |
| Debt Repayment | (98K) | (159K) | (158K) | (274K) | (373K) |
| Common Stock Issued | 0 | 0 | 135.62M | 53.54M | 178.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (804K) | (157K) | (5.79M) | 763K | 16.77K |
| Financing Cash Flow | 55.19M | 1.71M | 129.67M | 54.03M | 178.6M |
| Effect of Forex Changes | (16K) | 418K | (3.08M) | 407K | 174.39K |
| Net Change in Cash | 41.33M | (26.49M) | 18.54M | (10.62M) | 57.17M |
| Free Cash Flow | (13.85M) | (28.62M) | (53.89M) | (47.73M) | (62.51M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$94.5M
+ D&A$546.0K
+ Stock-Based Comp$16.0M
+ Deferred Tax$0
- Working Capital-$70.7K
+ Other Non-Cash$15.8M
= Operating Cash Flow-$62.2M
- Capex-$287.5K
= Free Cash Flow-$62.5M
Analysis
FY2025 free cash flow is -$62.5M. FCF conversion is 66.1% of net income. Operating cash flow was -$62.2M, with capex of -$287.5K. The largest bridge item is Stock-Based Comp at $16.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 3, 2026 | |
| 424B5 | 424B5 filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Sep 30, 2026 | |
| 6-K | 6-K filing | Aug 10, 2026 | |
| S-8 | S-8 filing | Aug 6, 2026 |
Does OCS generate free cash flow?
Oculis Holding AG (OCS) generated -$62.51M of free cash flow in fiscal 2025.
How much operating cash flow does OCS produce?
Operating cash flow was -$62.22M, before capital expenditures of $287,470.00.
Continue the stock analysis
Jump to another research area for this company.